Skip to main content
. Author manuscript; available in PMC: 2006 Jun 30.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1696–1702. doi: 10.1167/iovs.05-1258

Figure 5. Restoration of MMP-2 activity requires both MMP-14 and TIMP-2.

Figure 5

Representative zymogram (A) and graph depicting the mean ± SEM of duplicate experiments (B) of RPE cells transiently transfected with either a full length transcript of MMP-14 (lanes 4 –10) or TIMP-2 (lanes 11 and 12). Cells were treated with decreasing concentrations of recombinant TIMP-2 (rTIMP-2, nM) and injured according to the standard protocol described in methods (lanes 6–10). Only those cells with MMP-14 and the appropriate concentration of TIMP-2 had restored MMP-2 activity (lanes 9 and 10). Lane 3: recombinant TIMP-2 treatment to cells without injury (C=control, I= injury). Data are expressed as arbitrary densitometry units and represents three individual experiments performed in duplicate.